Methods and compositions for the treatment of CNS-related conditions

  • US 8,293,794 B2
  • Filed: 04/02/2010
  • Issued: 10/23/2012
  • Est. Priority Date: 04/06/2005
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical composition comprising:

  • (a) 5 to 40 mg memantine or a pharmaceutically acceptable salt thereof provided in an extended release dosage form, wherein said extended release memantine or pharmaceutically acceptable salt thereof provides a change in plasma concentration as a function of time (dC/dT) in a defined time period of 0 to 6 hours after administration, as measured in a single-dose human PK study, that is less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine during said defined time period; and

    (b) a therapeutically effective amount of an ACheI or a pharmaceutically acceptable salt thereof selected from the group consisting of donepezil, rivastigmine and galantamine.

View all claims

    Thank you for your feedback